G
GoodRx
Provides health consumers with convenient and affordable prescription drugs
At a glance
- Status
- Listed
- Listing
- IPO 2020
Open roles
GoodRx in the Santa Monica ecosystem
The GoodRx office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed10 investors entered at this stage
- DLDawn Lepore
Soma Capital
Lerer Hippeau- FPFrancisco Partners
Spectrum Equity
Upfront Ventures
SV Angel
Highland Capital Partners
Michael Ovitz
Founders Fund
Series B and later2 investors entered at this stage
Source: Dealroom Talent Intelligence.
Alumni founders
Former GoodRx employees who went on to found companies, sorted by Dealroom signal score.
TLTrial LibraryEst. 2022
Bryan PollardUnited States
Bret HarrisUnited States
Kyle AlwynUnited StatesPatents
3 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where GoodRx was the backer or acquirer, 2012–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
7 deals across GoodRx's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Where GoodRx deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
GoodRx's portfolio, mapped.
See GoodRx on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Behavior-simulation startup Vectorial raises $3M seed to replace consumer surveys
Spectrum Equity closes oversubscribed $2.5B Fund XI

